Hoth Therapeutics Statistics
Share Statistics
Hoth Therapeutics has 6.90M shares outstanding. The number of shares has increased by 58.84% in one year.
| Shares Outstanding | 6.90M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 28.83% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 6.84M |
| Failed to Deliver (FTD) Shares | 11.07K |
| FTD / Avg. Volume | 0.95% |
Short Selling Information
The latest short interest is 620.78K, so 8.99% of the outstanding shares have been sold short.
| Short Interest | 620.78K |
| Short % of Shares Out | 8.99% |
| Short % of Float | 9.08% |
| Short Ratio (days to cover) | 0.44 |
Valuation Ratios
The PE ratio is -0.63 and the forward PE ratio is -1.27.
| PE Ratio | -0.63 |
| Forward PE | -1.27 |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | 0.56 |
| P/FCF Ratio | -0.58 |
| PEG Ratio | n/a |
Enterprise Valuation
Hoth Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 13.89, with a Debt / Equity ratio of 0.
| Current Ratio | 13.89 |
| Quick Ratio | 13.89 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.33 |
| Cash Flow / Debt | -292.91 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.89% and return on capital (ROIC) is -86.72%.
| Return on Equity (ROE) | -0.89% |
| Return on Assets (ROA) | -0.82% |
| Return on Capital (ROIC) | -86.72% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -3.92M |
| Employee Count | 2 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -32.5% in the last 52 weeks. The beta is 0.84, so Hoth Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.84 |
| 52-Week Price Change | -32.5% |
| 50-Day Moving Average | 0.85 |
| 200-Day Moving Average | 0.99 |
| Relative Strength Index (RSI) | 43.25 |
| Average Volume (20 Days) | 1.16M |
Income Statement
In the last 12 months, Hoth Therapeutics had revenue of $0 and earned -$7.85M in profits. Earnings per share was $-2.3.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -7.69M |
| Net Income | -7.85M |
| EBITDA | -153.15K |
| EBIT | - |
| Earnings Per Share (EPS) | -2.3 |
Balance Sheet
The company has $9.29M in cash and $55.16K in debt, giving a net cash position of $9.24M.
| Cash & Cash Equivalents | 9.29M |
| Total Debt | 55.16K |
| Net Cash | 9.24M |
| Retained Earnings | -52.94M |
| Total Assets | 8.31M |
| Working Capital | 7.43M |
Cash Flow
In the last 12 months, operating cash flow was -$8.45M and capital expenditures $0, giving a free cash flow of -$8.45M.
| Operating Cash Flow | -8.45M |
| Capital Expenditures | 0 |
| Free Cash Flow | -8.45M |
| FCF Per Share | -2.48 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
HOTH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -283.95% |
| FCF Yield | -151.05% |
Analyst Forecast
The average price target for HOTH is $4.5, which is 455.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.5 |
| Price Target Difference | 455.6% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Oct 26, 2022. It was a backward split with a ratio of 1:25.
| Last Split Date | Oct 26, 2022 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -8.17 |
| Piotroski F-Score | 2 |